EMEA-001094-PIP01-10-M04 - paediatric investigation plan

Teriflunomide

Key facts

• Invented name:
  • Aubagio
  • Aubagio
• Active Substance:
  Teriflunomide
• Therapeutic area:
  Neurology
• Decision number:
  P/0165/2017
• PIP number:
  EMEA-001094-PIP01-10-M04
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of multiple sclerosis
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Genzyme Europe B.V. / Sanofi-Aventis groupe

  The Netherlands; Tel. [phone]; E-mail: [e-mail];

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  03/07/2017

Decision

P/0165/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for teriflunomide (Aubagio), (EMEA-001094-PIP01-10-M04)

AdoptedReference Number: EMA/354119/2017